SBIR/STTR Research Award
A Self-Contained Assay Device for Rapid Detection of Viable Cryptosporidium in Wa
Award amount
$142,383Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Biodetection Instruments, Inc
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- PA13-088
- Topic code
- NIAID
Research abstract
DESCRIPTION (provided by applicant): This Small Business Innovation Research Phase I project will investigate the technical feasibility of an in vitro excystation-based automated cartridge assay for rapid detection of viable Cryptosporidium oocysts in water. Briefly, viable oocysts will be subjected to an in vitro excystation step to release sporozoites and the antigens for detection on a patent-pending self- contained cartridge immunoassay system. The Phase I research will focus on demonstrating the feasibility of specific detection of viable oocysts with a direct detection limit (i.e., without sample preconcentration) of d100-1000 oocysts/mL within in 1-2 h, which will be improved in Phase II to achieve the detection of d100 oocysts/10 L with sample preconcentration. The proposed assay will ultimately be highly automated and provide quantitative results for viable oocysts within 4 h from sample acquisition, largely reducing the complexity and lengthiness of current standard methods and allowing for ne
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients